Results 21 to 30 of about 144,610 (311)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Neoadjuvant therapy for pancreatic cancer [PDF]

Updates in Surgery, 2021
Multimodal treatment including surgery and chemotherapy is considered the gold standard treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been seen as a possible treatment option for resectable, borderline resectable and locally advanced PaC.
Jean Gugenheim, Anna Crovetto, Niccolo Petrucciani   +2 more
openaire   +2 more sources

Management of inoperable endometrial cancer [PDF]

Obstetrics & Gynecology Science, 2022
Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types of treatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatment before surgery. Radiation therapy
Supakorn Pitakkarnkul, Saranya Chanpanitkitchot, Siriwan Tangjitgamol   +2 more
doaj   +1 more source

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

, 2023
Pancreatic ductal adenocarcinoma (PDAC) is a challenging disease process with a 5-year survival rate of only 11%. Neoadjuvant therapy in patients with localized pancreatic cancer has multiple theoretical benefits, including improved patient selection for
Anish J. Jain, Matthew H. G. Katz, Jessica E. Maxwell, Rebecca A. Snyder   +3 more
core   +1 more source

Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)

Zhongguo aizheng zazhi, 2022
Neoadjuvant therapy has become one of the standard treatments in early breast cancer. In 2019, China breast cancer neoadjuvant therapy expert group discussed and expounded the purpose, indication, evaluation criteria, surgical operation principles and ...
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)
doaj  

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer, 2021
Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data
Mary Kathryn Abel, Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola Hylton, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Judy C. Boughey, Rita A. Mukhtar   +11 more
doaj   +1 more source

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma

Journal of the National Cancer Center, 2022
: Objective: This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC ...
Zhen Wang, Xiankai Chen, Yong Li, Jianjun Qin, Yuan Fang, Zhaoyang Yang, Yan Fang, Dong Qu, Ruixiang Zhang, Qingfeng Zheng, Xiaozheng Kang, Liyan Xue, Jing Huang, Yin Li, Jie He   +14 more
doaj   +1 more source

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear.
Zhen Liu, Zimu Zhang, Juan Sun, Jie Li, Ziyang Zeng, Mingwei Ma, Xin Ye, Fan Feng, Weiming Kang   +8 more
doaj   +1 more source

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Oncology, 2021
BackgroundImmune checkpoint inhibitors (ICIs) have shown promising anti-tumor activity in multiple malignances including breast cancer. However, the responses can vary.
Yunhai Li, Lei Xing, Fan Li, Hong Liu, Lu Gan, Dejuan Yang, Mengxue Wang, Xuedong Yin, Hongyuan Li, Guosheng Ren, Guosheng Ren   +10 more
doaj   +1 more source

Supersensitive PSA-Monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow [PDF]

, 1998
Objective: The present study was done to investigate the effects of supersensitive PSA-controlled inductive treatment on positive margins, detection of tumor and epithelial cells in bone marrow of 101 patients with untreated and clinically localized ...
Köllermann, J., Kaulfuss, U., Spitz, J., Enzmann, Th., Köllermann M. W., Feek, U., Martell, W., Kossiwakis, M.   +7 more
core   +1 more source